Drug Profile
Davoceticept - Alpine Immune Sciences
Alternative Names: ALPN-202; PD-1/CTLA-A Antagonist and CD28 Agonist - Alpine Immune SciencesLatest Information Update: 28 Sep 2023
Price :
$50
*
At a glance
- Originator Alpine Immune Sciences
- Class Antineoplastics; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD28 antigen stimulants; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Lymphoma; Solid tumours
Most Recent Events
- 28 Sep 2023 No recent reports of development identified for phase-I development in Lymphoma(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
- 05 Jun 2023 Alpine Immune Sciences terminates the phase I NEON-2 trial in Lymphoma (In adults, In the elderly, Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Late-stage disease) and Solid tumours (Combination therapy, In adults, In the elderly, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT04920383)